Reprogramming the Gut–Metabolic Axis: Microbiota Dynamics, Causal Mechanisms, and Therapeutic Prospects in Metabolic Disease
gut microbiota; metabolic dysfunction; obesity; type 2 diabetes; NAFLD; dysbiosis; short- chain fatty acids; bile acids; insulin resistance; intestinal permeability; inflammation; Akkermansia muciniphila; Faecalibacterium prausnitzii; GLP- 1 signaling; FXR; metabolic endotoxemia; microbiome therapeutics; precision medicine; host–microbe interaction; causal inference
AuthorsAbstractBackground: The gut microbiota constitutes a metabolically active interface between diet, host physiology, and metabolic health. Growing evidence implicates microbial dysbiosis in the onset and progression of obesity, type 2 diabetes (T2D), and non- alcoholic fatty liver disease (NAFLD) through mechanisms that extend beyond mere association. Yet, defining causality within this intricate host–microbe network remains an unresolved frontier. Objective: This study critically examines causal pathways linking gut microbial alterations to metabolic dysfunction, synthesizing insights from experimental and translational research to identify mechanistic determinants and therapeutic leverage points within the gut–metabolic axis. Methods: A conceptual, evidence- based synthesis was conducted, integrating findings from longitudinal human cohorts, gnotobiotic and fecal microbiota transplantation models, and clinical interventional trials published between 2015 and 2025. Priority was given to studies employing causal inference frameworks, isotope- tracing metabolomics, and mechanistic mapping of microbial metabolites. Key Findings: Microbial communities influence glucose and lipid homeostasis through the modulation of bile acid pools, short- chain fatty acid (SCFA) production, and branched- chain amino acid metabolism. Loss of butyrate- producing genera (Faecalibacterium, Roseburia) and expansion of pathobionts disrupt epithelial integrity, fostering systemic inflammation and insulin resistance. Conversely, restoration of taxa such as Akkermansia muciniphila and engineered Bacteroides strains enhances mucosal signaling via GLP- 1 and FXR pathways, improving metabolic outcomes (Lynch & Pedersen, 2016; Thaiss et al., 2018). Conclusion: The gut microbiota operates as a causal modulator rather than a passive correlate of metabolic disease. Decoding its mechanistic influence unveils novel translational opportunities, from microbiota- targeted therapeutics to individualized metabolic interventions redefining chronic disease management.
IntroductionMetabolic diseases—chiefly obesity, type 2 diabetes (T2D), and non- alcoholic fatty liver disease (NAFLD)—have reached epidemic proportions over the past three decades, undermining global public health and economic stability. According to the World Health Organization, more than 1 billion adults are now classified as overweight or obese, a figure projected to double by 2035 if current trajectories persist (WHO, 2024). Parallel to this rise, T2D affects nearly 540 million people worldwide, accounting for an estimated 12 percent of global healthcare expenditure (Cho et al., 2023). NAFLD has similarly emerged as the most prevalent chronic liver disorder, affecting roughly one in four adults, with mounting evidence linking it to cardiovascular morbidity and extrahepatic complications (Younossi et al., 2023). •••••••••••••••••••••••••••••••• ejprd.org- Published by Riset Publishing Services LLC.
EJPRD
Copyright © 2026 by Riset Publishing Services LLC